43,833 Shares in CVS Health Corporation $CVS Bought by North Dakota State Investment Board

North Dakota State Investment Board purchased a new position in shares of CVS Health Corporation (NYSE:CVS) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 43,833 shares of the pharmacy operator’s stock, valued at approximately $3,479,000.

A number of other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in CVS Health by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock worth $9,579,508,000 after acquiring an additional 1,824,424 shares during the last quarter. Capital World Investors boosted its position in CVS Health by 2.1% during the 3rd quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock worth $5,155,380,000 after acquiring an additional 1,419,575 shares during the last quarter. State Street Corp boosted its position in CVS Health by 0.3% during the 3rd quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator’s stock worth $4,443,357,000 after acquiring an additional 149,701 shares during the last quarter. Capital International Investors boosted its position in CVS Health by 1.1% during the 3rd quarter. Capital International Investors now owns 26,692,203 shares of the pharmacy operator’s stock worth $2,012,347,000 after acquiring an additional 302,499 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in shares of CVS Health by 3.2% during the 3rd quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock worth $1,831,454,000 after buying an additional 760,579 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insider Buying and Selling

In related news, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares of the company’s stock, valued at $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.85% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently weighed in on CVS. Truist Financial raised their price objective on CVS Health from $98.00 to $102.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Wells Fargo & Company raised their price target on CVS Health from $102.00 to $103.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Leerink Partners reaffirmed an “outperform” rating and set a $98.00 price target on shares of CVS Health in a report on Thursday, March 5th. JPMorgan Chase & Co. raised their price target on CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Finally, TD Cowen raised their price target on CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a report on Monday, May 11th. Twenty-two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $98.08.

CVS Health Trading Up 0.1%

Shares of CVS stock opened at $95.95 on Monday. The firm has a 50 day moving average price of $78.71 and a two-hundred day moving average price of $78.57. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $122.42 billion, a PE ratio of 42.27, a price-to-earnings-growth ratio of 0.94 and a beta of 0.60. CVS Health Corporation has a 12-month low of $58.50 and a 12-month high of $98.43.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The company had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. CVS Health’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were given a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date was Thursday, April 23rd. CVS Health’s payout ratio is presently 117.18%.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Morgan Stanley raised its price target on CVS Health and kept an overweight rating, signaling confidence in further upside after the company’s stronger-than-expected quarterly results. Morgan Stanley Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price
• Positive Sentiment: Argus also lifted its outlook for CVS Health, adding to the wave of analyst support that may be helping shares move higher. Argus Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price
• Positive Sentiment: CVS reported solid Q1 2026 earnings recently, beating estimates on both revenue and adjusted EPS, which continues to drive investor optimism about execution and valuation. Here is Why CVS Health (CVS) is One of the Cheap Stocks to Buy For the Next 10 Years
• Positive Sentiment: CVS and WGU launched an online pre-pharmacy degree program to help build a stronger pharmacist pipeline, a move that could support long-term staffing and service growth. CVS Health® and WGU launch online pre-pharmacy degree program for future pharmacists nationwide
• Neutral Sentiment: CVS advanced its portfolio reset by selling Omnicare after bankruptcy court approval, which simplifies the business and removes an underperforming unit, but also confirms ongoing restructuring. CVS Refocuses On Core Health Platform With Omnicare Sale And Drone Rollout
• Neutral Sentiment: CVS also highlighted community and brand-building initiatives in Rhode Island, including its economic impact report and expanded WIC acceptance, which are positive for reputation but less likely to move the stock on their own. CVS Health’s Annual Impact in Rhode Island

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.